Product information
| Price | €175, €275, €395 |
|---|---|
| Size | 20 µl/µg | 50 µl/µg | 100 µl/µg |
| Short name | ANKRD30A Antibody |
| Host | Rabbit |
| Isotype | IgG |
| Target protein | ANKRD30A |
| Recommended applications | ELISA, IHC-p, WB |
| Reactivity | Human |
| Immunogen | The antiserum was produced against synthesized peptide derived from human AN30A. AA range:1041-1090 |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Formulation | Liquid in PBS containing 50% glycerol; 0.5% BSA and 0.02% sodium azide. |
| Storage | -20°C for 1 year |
| Product code | MB-AP11805 |
Additional information
Prev
Next
Ankyrins are membrane adaptor molecules that play important roles in coupling integral membrane proteins to the spectrin-based cytoskeleton network. Mutations of ankyrin genes lead to severe genetic diseases, such as fatal cardiac arrhythmias and hereditary spherocytosis. ANKRD30A (ankyrin repeat domain 30A), also known as serologically defined breast cancer antigen NY-BR-1, is a 1,397 amino acid coiled-coil protein. Containing six ANK repeats and thirty-seven exons, ANKRD30A is a distant homolog of the POTE family. Initiated by either Dnmt1 or Met-57, ANKRD30A is highly expressed in breast and testis, and faintly in placenta. Present in 80% of breast cancers, but not in other types of tumors, ANKRD30A is a differentiation antigen and a potential target for antibody‐based therapies in breast cancers.
ANKRD30A, Ankyrin repeat domain-containing protein 30A, Serologically defined breast cancer antigen NY-BR-1
Human: Q9BXX3
Human: 91074
